News

Price Chopper Pharmacies announce availability of flu vaccines

BY Antoinette Alexander

SCHNECTADY, N.Y. — Price Chopper has announced that its pharmacies are now carrying the flu vaccine and Price Chopper’s pharmacists can administer it — with no appointment necessary — for anyone over the age of 19 years.

“This is the time that people should be looking to get the flu vaccination, not after flu activity peaks and you are at a high risk to get it,” said Kathy Bryant, Price Chopper’s VP of pharmacy.

Price Chopper Pharmacy carries the Quadrivalent flu vaccine, offering greater protection to the patient. Quadrivalent offers protection against an additional strain of the flu virus, increasing the chances that the strains included in the vaccine will cover this season’s virus.  Also available is the Thimerosal-free and High Dose flu vaccines for those older than 65 years of age.

The Centers for Disease Control and Prevention recommends that patients get vaccinated as soon as the vaccine becomes available. Flu activity is seen in communities as early as October and typically peaks in the months of December and February. The CDC recommends everyone over the age of six months be vaccinated.

The flu can lead to many complications such as sinus infections, pneumonia, bronchitis, and even death. This is especially a concern for patients with such diseases as heart disease or diabetes and patients that are over the age of 65 years.

Price Chopper Pharmacies accept most insurance plans, including Medicare, often times with zero out of pocket cost to the patient.

“Pharmacists can help increase access to routine immunizations and can impact vaccination rates to avert vaccine preventable diseases. The expanded immunization program at Price Chopper is another way of helping our guests with accessible and affordable health care, particularly when they need it most," Bryant added.

Price Chopper Pharmacists also offer a variety of adult vaccinations including shingles, pneumonia, pertussis, tetanus and meningococcal shots. Some vaccinations are not available in all pharmacy locations.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

New wearable, in-home hair growth device gets OTC clearance

BY Antoinette Alexander

BOCA RATON, Fla. — Apira Science’s iGrow Hair Growth System is the first wearable, hands-free, in-home hair growth device to receive OTC clearance from the Food and Drug Administration for hair growth in men, the company has announced.

According to Apira Sicence, the iGrow Hair Growth System can increase hair counts by 35% in 16 weeks of therapy. The device promises to offer a convenient, cost-effective and clinically proven solution for androgenetic alopecia — patterned baldness — an ailment affecting more than 70% of American men. According to the company, iGrow's LLLT technology has no side effects.

The system’s red-light technology, which consists of a combination of red laser and LED diodes, re-energizes cells at the follicle level to regrow hair. In the clinical study, which was awarded the Best Overall Experimental and Translational Research Award by The American Society for Laser Medicine and Surgery Inc., the iGrow re-grew hair 10 weeks faster than hand-held laser combs and brushes, according to the company.

The iGrow Hair Growth System is now available for purchase at www.igrowlaser.com; retail sites NeimanMarcus.com, Nordstrom.com, Bedbathandbeyond.com, Hammacher.com, Drugstore.com and Frys.com; and also at select Neiman Marcus, Nordstrom, Bed Bath & Beyond and Fry’s retail locations.

The device, which comes with a six-month, money-back guarantee, retails for $695.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Roche launches blood-glucose meter with built-in insulin dose calculator

BY Michael Johnsen

 
 
INDIANAPOLIS — Roche on Tuesday announced that the Accu-Chek Aviva Expert system is now available by prescription. The device represents a significant advancement in blood-glucose meter technology for people with diabetes who take multiple daily insulin injections, Roche stated. The meter's integrated bolus calculator provides easy-to-use and reliable dose recommendations based on automated calculations, eliminating the need for manual dosing calculations and estimations. A survey of Accu-Chek Aviva Expert users found that 79% reported increased confidence with insulin dose calculation, and 52% reported a reduced fear of hypoglycemia.
 
"The Accu-Chek Aviva Expert system is the first and only system of its kind that provides meal and correction insulin bolus recommendations, which can help patients on insulin therapy have the confidence they need to better manage their diabetes," said Marc Gibeley, head of Roche Diabetes Care North America.
 
"The availability of the Accu-Chek Aviva Expert system marks an important, game-changing milestone in diabetes self-management by making the process of calculating insulin dosage easier and less susceptible to error," said Bruce Bode, a clinical associate professor in the department of medicine at Emory University and a diabetes specialist with Atlanta Diabetes Associates. "One of the biggest barriers to optimal self-management is the ability to calculate bolus doses. My hope is that the device will become the standard of care for patients on multiple daily insulin injection therapy due to the simplicity of the built-in bolus calculator."
 
In the United States, approximately 6 million people take insulin to help manage their diabetes. Many people also take multiple daily injections of insulin to help manage their disease, which requires them to calculate proper insulin dosage amounts based on their food intake and blood-glucose readings. These calculations are complex, and constant precision is critical to determine the proper insulin dose. A multicenter study found that 63% of manually calculated insulin doses were incorrect. Researchers from the Centers for Disease Control and Prevention reported that there were nearly 100,000 emergency room visits each year between 2007 and 2011 that were attributed to insulin-related hypoglycemia and other errors, and that these visits accounted for roughly 9% of all ER visits due to drug reactions during this timeframe.
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?